Page 1 of 6

		ILS DEP	ARTMENT OF C	OMMERCE	ATTY. DOCKET CV01148KB	NO.:	SERIAL NO 10/777,84	5.: .9	
RM PTO-	1449		ANDIRAUENW		ADDITIONT:		<u> </u>		
		TION DISCLOS	URE STATE	MENT	Chackalaman	ıll et al.			
INFO	RMA	BY APPLIC	ANT						
		BA WELLIO		A	FILING DATE: 02/12/2004		1624		
	// [9/	several sheets	if necessary	<u>"</u>					
	100		LLC DAT	ENT DOCU	MENTS		COUR K	ILING DATE IF	
			T DATE	N/	ME	CLASS	SUB-	APPROPRIATE	
XAMINER	1 	DOCUMENT	DATE			514	25B	-	
INITIAL	4 1	NUMBER	10/05/1993	Bell et al.		530	327		
W	AB	5,250,534	10/26/1993	Coughlin		1630	26336		
9	AC	5,256,768	06/14/1994	Maschler et a	<u>!</u>	514	258		
	AD	5,321,029	09/13/1994	Bell et al		514	233.2		
	AE	5,346,901	02/28/1995	Neustadt et a	<u>/</u>	514	263.33		
	AF	5,393,755	04/25/1995	Smith et al.		424	450	 	
	AG	5,409,934	11/28/1995	Bonte et al.			227	 	
		5,470,579	06/10/1997	Porter et al.		514	15	 	
	AL	5,837,593	11/18/1997	Coughlin et a	ıl	514	262	 	
	AJ	5,688,768	02/17/1998	Bell et al		544	9	 	
	AK	5,719,283	06/02/1998		<u> </u>	614	214	 	
	AL	5,769,994	08/25/1998	Coughlin et	al	435	257	+	
	AM	5,798,248	10/20/1998	McKittrick et	al	514	388.22		
	AN	5,824,683	01/05/1999			530	249	 	
	AO	5,858,448	01/12/1999			514	258	+-+-	
	AP	5,859,008	02/23/1999			514	573	+	
	AQ	5,874,437	03/02/1999	Place et al		514	257	++	
	AR	5,877,216	08/17/1999		al	514	262	+	
	AS	5,939,419	09/21/1999			544		- 	
	AT	5,955,611	09/28/1999	Garvey et a		514	253 250		
	AU		11/09/1998		al	514	1250 1765	s -	
	AV		11/09/1999		d	514	- 2		
	AW		02/08/2000	Ross, Jess	<u> </u>	607	1.49		
	AX	6,023,640	02/16/200		al	424	64		
	- AY		02/15/200			546	258		
	AZ		03/14/200	0 Doherty, Jr		514	400	5	
	BA	6,037,346	04/18/200		ed	514	132	[- - - - - - - - - 	
	BE		05/23/200	O Dunn et al.		544	252	``\	
	BC		07/11/200	0 El-Rashidy	, Ragab	514	258	`	
	BE	6,087,382	08/08/200	0 Campbell		514	7.1		
	BI		09/26/200			435 514	250		
	<u> B </u>	= 6.124,101 - 6.140,339	10/31/200	Daugan_		514	249		
		6,140,329 H 6,143,748	11/07/200		al	435	69.1		
	B	1000 04	03/08/20	01 Coughlin		435 514	218		
	B		03/26/20	2 Niewohne		514	256	-	
	В	100 000 004	08/11/20	02 Wilson et	<u> </u>	514	258		
			10/22/20	02 Ellis et al			262	 	
		- 400 040 D4	10/22/20		<u>/</u> _	514	573	- 	
¥		M 8,469,016 B1	10/29/20	02 Place et a		514		- - 	
		N 6,472,434 B1 O 6,512,002 B2	01/28/20			514	421		

Sudlah Blob

1/8/05

Page 2 of 6

			PATENT DOCUMENTS	CLASS	SUB-	TRANSL	INO
	TROUNTENT	DATE	COUNTRY	l	CLASS	YES	NO_
	CR NUMBER		EPO		<u> </u>	+=	 = -
40 /	CC EP 0 258 191 A1	02.03.88	EPO		-	+-=	
```	CD FP 0 389 282 A2	26.09.90	EPO	1	1-	+	+
4	CE EP 0 463 758 A1	02.01.92	EPO				+-=
 -	CE FP D 389 282 A2	26.09.90	EPO	↓_	 	+	 - -
	CG EP 0 389282 A3	26.09.90 26.09.90	EPO	<u> </u>	 		
_	CH EP 0 389 282 B1	26.09.90	EPO		 	+	1
	CI 0 389 282 A2	02.01.92	EPO	 -	+		
1	CJ 0 463 756 B1	03.02.93	EPO		+	+=	1=
	CK 0 528 004 A1	27.03.96	EPO		+=		
	CL 0 702 565 B1	07.1992	PCT	+=	+ =	_	1=
	CM WO 92/11260 CN WO 91/19717	26.12.91	PCT		 		-1 =
		13.08.91	PCT (in French)	+	-	- X	
—		13.06.91	PCT (English Translation)	+-=		= =	
—∔—	CP WO 91/07945 A1	02.04.92	PCT	+=	-	-1 =	
	CR WO 92/11260	09.07.92	PCT		_	=	<u> </u>
_	CS WO 93/23401	25.11.93	PCT				
-+-	CT P 19 38 016.6	28.01.71	Germany				_
-+-	CU WO 94/28902	22.12.94	PCT				
-+-	CV WO 99/54331	02.04.92	PCT (in German) PCT (English Translation)		T	X	
+-	CW WO 89/54331	28.10.99					
-+-	CX WO 92/05175	02.04.92					
	CY WO 99/62905	09.12.99		丁三		_	
_	CZ WO 99/24433	20.05.99			حـــــــــــــــــــــــــــــــــــــ		
	DA FR 2.116.302	13.07.72	WIPO				
	DB 89/10123	02.11.89 26.12.91		=		=	
	DC 91/19717	02.04.92	14400			=- -	
	DD 92/05175	02.04.92					
	DE 92/05176	25.11.93			=1		=+-
	DF 93/23401	01.09.94					- -
	DG 94/19351	06.06.90			- -	=+=	=+-
	DH 98/16644	06.06.9			- -	- + -	
	DI 96/16657	17.10.9				- -	
	DJ 96/32379	06.02.9					
	DK 97/03985	10.07.9				- -	
		20.11.9				 ,	
		05.03.9			=1-		
		16.4.9	8 WIPO				
	DO 98/15530 DP 98/38168	03.09.9					
	DQ 98/49166	06.11.9	8 WIPO	- 			\neg
+	DR 99/00359	07/01/9	9 WIPO	- + -		_	$\equiv \Gamma$
	DS 99/00373	07/01/9		- -			
	DT 99/21558	06.05.					
	DU 99/21831	08.05.					=
 	7 DV 99/42452	28.08.					$\equiv \Gamma$
├──∀	// DW 99/43674	02.09.		 -	;		
 		02.09.			=	\equiv I	
⊢ ≪	DX 99/43679 DY 99/64333	28.10.	99 WIPO				
- 9	/- - - - - - - - - - - - - -						
1.0							
							
-							
							
-							
<u> </u>	_ 	T	<u> </u>				l

Page 3 of 6

			Company State
_			R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
		HE	R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Elso, Position of
	TEA	TUC	R DOCUMENTS (Including) Sam Ahn et al. "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanine Sam Ahn et al. "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanine Document of the Coll Disease I. Effect of
WO.	∕∤ ट^	1 34	anophosphate Phosphodiesterases with Oral Astally
Na/		1 40	NA 12. 00. 2 130 ST. Carle of Sickle Cell Discour.
24_	-\	1 477	L. Ambrus et al. "Studies on Vascocciusive Crisis of State (1979). L. Ambrus et al. "Studies on Vascocciusive Crisis of State (1979). Entoxifylline", Journal of Medicine", Vol. 10, No. 6, pp. 445-458 (1979). Entoxifylline", Journal of "Preparation of Water-Soluble Compounds Through Salt Formation", pp. 739-
Į.	EB	13.	L. Ambrus et al. "Studies of Value", Vol. 10, No. 6, pp. 445-458 (1979). entoxifylline", Journal of Medicine", Vol. 10, No. 6, pp. 445-458 (1979). entoxifylline", Journal of Medicine", Vol. 10, No. 6, pp. 445-458 (1979). entoxifylline", Journal of Medicine (New York, pp. 739- radley D. Anderson et al. "Preparation of Water-Soluble Compounds Through Salt Formation", radley D. Anderson et al. "Studies of Medicine", Vol. 10, No. 6, pp. 445-458 (1979).
		15	entoxifyiline", Journal of medicine of Water-Soluble Compounds Through Salt of the radies of Medicine of Water-Soluble Compounds Through Salt of the Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Press, New York, pp. 739-the Practice of Medicinal Chemistry, C. G. Wermuth, Ed., Academic Press, New York, pp. 739-the Press, New York, pp. 7
1	EC		Bodica of Medicinal Chemistry, C. G. Wermuth, Ed., Adda
l	- 1	123	he Practice of Medicinal Ottomoty, the Practice of Medicinal Ottomoty, Protein 54 (1996). 1.I. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein I.I. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II.I. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II.I. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II.I. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein II. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase III." Argel et al. "Effect of Phosphodiesterase Inhibitors on Heart Contractile Behavior, Protein III. Argel et al. "Effect of Phosphodiesterase III." Argel et al. "Ef
		40	34 (1995). The state of Phosphodiesterase inhibitors on Heart Vol. 12 No. 10, pp. 939-954,
-	ED		
l	l l	١ĸ	bstract (1980). Annold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine in Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine In Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine In Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine In Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine In Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Traditional Medicine In Venda", Journal of Itans-Joachim Arnold et el, "Pharmacopoeta of Itans-Joachim Arno
ᆫ			bstract (1960).
	- IEE	ĔĮĦ	lans-Joachim Arnold 67 81, 1 Market 1984). Sthrophermacology, Vol. 12, pp. 35-74 (1984). Sthrophermacology, Vol. 12, pp. 35-74 (1984). William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William J. Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William Aronson et al, "The Mediator of Human Corpus Cavernosum Relaxation is Nitric Oxide", William Cavernosum Relaxation is Nitric Oxide", William Cavernosum Relaxation is Nitric Oxide
	L_	<u> </u>	Unnopharmacology, Volume Mediator of Human Corpus Cavernosum Relaxeton to Mills Office Vision Corpus Cavernosum Relaxeton Cavern
	\EI	= V	William J. Aronson et al, "The Mediator of Human Corpos William J. Aronson et al, "The Mediator of Human Corpos The Journal of Urology, Vol. 145, No. 4, p. 341A, Abstract No. 516 (1991). The Journal of Urology, Vol. 145, No. 4, p. 341A, Abstract No. 516 (1991).
1	1	. 17	The Journal of Crology, vol. 1-45, 1
	E	<u> </u>	loseph A. Besvo, "Cyclic Nucleons", 127 Apr. 728 748 (October 1995).
1	1		DAVENDONICAL REVIEWS, VVII. VIII. VIIII. VIII. V
	E	ĦŢ,	soforms ", Physiological Reviews, Vol. 75, No. 6, pp.726-7-3 (cyclic nucleotide Joseph A. Beavo & David H. Reifanyder, "Primary sequence of cyclic nucleotide Joseph A. Beavo & David H. Reifanyder, "Primary sequence of cyclic nucleotide Joseph A. Beavo & David H. Reifanyder, "Primary sequence inhibitors", Trends in Pharmacological
.			- bank Adjociarasp isozyi i es di o dio designi.
	1	- 13	Sciences, Vol. 11, No. 4, pp. 150-155 (April 1990). Sciences, Vol. 11, No. 4, pp. 150-155 (April 1990). Stephen M. Berge et al. Pharmaceutical Salts', J. of Pharmaceutical Sciences, Am. Pharm. Stephen M. Berge et al. Pharmaceutical Salts', J. of Pharmaceutical Sciences, Am. Pharm.
	E	7 1	Prochen M. Rarge et al. Pridifficeutodi Califf
.	· -	- 1.	Assoc. and Pergamon Press, Vol. 56, No. 1, pour people relaxation in the bovine retractor penis
_	15		AARO Bowman At Al. "CYCIIC GIVIP III GUIDIO TITOLOGICO
- 1	- 1-	•	muscle Rr. J. Phannec., Vol. 01, pp. 000-01, 120 Conduces Penile Erection in
 +			Wirone et al. letter to ed. le. initiacaroniose significant Vol. 74 No. 3 n. 365 (March 1995)
4	1-	"`	Patients with Erectile Dysfunction", British Journal of Urology, Vol. 71, 1999, Advances in Cyclic Gary Brooker et al, "Radioimmunoassay of Cyclic AMP and Cyclic GMP", Advances in Cyclic Gary Brooker et al, "Radioimmunoassay et al, Eds., Vol. 10, op. 1-33 (1979).
+			Con Brooker of al. "Radioimmunoassay of Control 4 22 (4070)
- 1			Nucleotide Research, Paul Greengald et al., 2001, political political in relevation of
+		- A	Nucleotide Research, Paul Greengard et al, Eds., Vol. 10, pp. 1-33 (1979). Nucleotide Research, Paul Greengard et al, Eds., Vol. 10, pp. 1-35 (1979). Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush, "The role of the L-arginine-nitric oxide-cyclic GMP pathway in relaxation of Margaret Ann Bush (Margaret Ann Bush) and Margaret Ann Bush (Margaret Ann Bus
1	15	ا بەد	ACCOURTED SUITS SITUATION TO THE STATE OF TH
.	- 1	1	Order No. 9319914) (179 pgs) (1993). Order No. 9319914) (179 pgs) (1993). Peggy Bush et al., "Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum".
	 ;		Pormy Bush et al. "Nitric Oxide is a Potent Relaxante
- 1	16	EN	Peggy Bush et al, "Nitre Oxfob 1650-1655 (June 1992). Journal of Urology, Vol. 147, pp. 1650-1655 (June 1992). S. Carrier et al, "Erectile Dysfunction," Endocrinology and Metabolism Clinics of North America: S. Carrier et al, "Erectile Dysfunction," Endocrinology and Metabolism Clinics of North America:
ıl	ļ,	EO	S. Carrier et al, "Erectile Dyslution," S. Carrier et al, "Erectile Dyslution," Clinical Andrology, Vol. 23, No. 4, pp. 773-782 (Dec. 1994). Clinical Andrology, Vol. 23, No. 4, pp. 773-782 (Dec. 1994).
			Clinical Andrology, Vol. 23, No. 4, pp. 773-782 (Dec. 1994). P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite of Flavoxate 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite 3- P. Cazzulani et al, "Pharmacological Activities of the Main Metabolite 3- P. Cazzulani et al, "Pharmacological Activities 3- P. Cazzulani et al, "Pharmacological Activities 3- P. Cazzulani et al, "Pharmacological Activities 3- P. Caz
F 1	l l	EP	P. Cazzulani et al, "Pharmacological Activities of the Math Matsborn." P. Cazzulani et al, "Pharmacological Activities of the Math Matsborn." Nethylflavone-8-carboxylic Acid", <i>Drug. Res.</i> , Vol. 38 (I), No. 3, pp. 379-382 (1988). Methylflavone-8-carboxylic Acid", <i>Drug. Res.</i> , Vol. 38 (I), No. 3, pp. 379-382 (1988).
			Methyfflavone-8-carboxylic Acid*, <i>Drug. Res.</i> , Vol. 38 (1), No. 3, pp. 378-382 (1993). Methyfflavone-8-carboxylic Acid*, <i>Drug. Res.</i> , Vol. 38 (1), No. 3, pp. 378-382 (1993). J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation into the role of Phosphodiesterase IV in Bronchorelaxation, including J. Cortijo <i>et al.</i> , "Investigation in the role of Phosphodiesterase IV in Bronchorelaxation in the role of Phosphodiesterase IV in the role of Phosphodiesterase IV in the role of Phosphodiesterase IV in the role
		EQ	J. Cortijo et al. "Investigation into the role of Phosphodiesterase". 562-568 (1993). Studies with Human Bronchus", Br. J. Pharmacol., Vol. 108, pp. 562-568 (1993).
1 1	l		Studies with Human Bronchus", Br. J. Pharmacol., Vol. 106, pp. 332 see isoenzymes: Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isoenzymes:
		ER	Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic nucleotide phosphodiesterase isodi Zymia. Jacob de Boer et al, "Human bronchial cyclic
1 1			hiochemical and pharmacological analysis come
1 1	i '	ļ.	l pp. 1028-1034 (1994).
 		ES	Dano Doller et al, "The GIF System as a Tool in Medicinal Chemistry. The Oxidate to SCH57726 under GOAGG III Conditions", Bioorganic and Medicinal Chemistry Letters, Vol. 7, I
1 '			I SCH57726 under GUAGG III COMMINIONS, CLOST COMMINIONS
1	!	l l	111 pp. 1381-6 (1997).
 		ET	Dukarm R.C., et al., (1999) The cGMP-specific Phosphodiesterase introduced to 160:858-865. Pulmonary Circulation. American Journal Respir. Crit. Care Med., Volume 160:858-865. Pulmonary Circulation. Facility Description: New Approaches", Orug Therapy, Vol. 8, pp. 102-
1	l	١	Pulmonary Circulation. American Journal Respir. Cit. Consequence Onto Therapy, Vol. 8, pp. 102-
 	├	EU	ILL Fishman. Treating Erectis Dystutions. The Treating Erectis Dystutions.
1	1	1	(August 1989).
<u> </u>		15/	(August 1989).
 	 	15%	I I C Cillegnie & J.A. Beavo, Infillium and Cantalana, Long as 772-781 (Nov. 1988)
		EV	P.G. Gillespie & J.A. Beavo, "inhibition and Stimulation of Photorecapion," 173-781 (Nov. 1988). Dipyridamole and M & B 22,948", Molecular Phermacology, Vol. 38, pp. 773-781 (Nov. 1988). Dipyridamole and M & B 22,948", Molecular Phermacology, Vol. 38, pp. 773-781 (Nov. 1988).
<u> </u>	 	+==	TIO OLAGOI of al "EMPRING UNANTIQUOIOSIOCI U.S. "F."
1	1		Petents, Vol. 9, No. 12, pp. 1689-1696 (1999). Petents, Vol. 9, No. 12, pp. 1689-1696 (1999).
		4_	
	[]E/	PRIND L. GOURD, Sak Selection to Tark
	1		201-217 (1986). Z Theodora W. Greene, "Protective Groups in Organic Synthesis". John Wiley & Sons, Inc., Nev
	7] EZ	7 Theodora W. Greatic, Protective Courts
1	Y _/		York, pp. 1-9 (1981). A Jain Gregoire, "Viagra: on release", BMJ, Vol. 317, p. 759-760 (Sept. 19, 1998).
- 1			A I Alain Gregoire, "Viagra: on release j brings."
	X 6	7 <u>5/</u>	La cha Sta

Page 4 of 6

		inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Hypoxic Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attenuates Inasato N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, (1990) E-4010, a Selective Phosphodiesterase 7 Inhibitor, (1990) E-4010, a Selective Phosphodiesterase 7 Inhibitor, (1990) E-4010, a Selective Phosphodiesterase 7 Inhibitor, (1990) E-4010, a Select
	_	inaseto N., et al., (1999) E-4010, a Selective Phosphodiesterase 5 Inhibitor, Attorney Aller Cell. Mol. islamonary Hypertension in Rats, American Journal of Physiol., Volume 277 (Lung Cell. Mol. 1205-1232)
	TFB H	massto N., et al., (1999) Pats, American Journal of Physiol., Volume 2.7
Wb.	J∕ 1₽	ilmonary hypertendent in the second and the second
Y'	1 10	WRIGH, ZIII, LZZO-CAU
-12/4-	FC T	harmaceutical Coloring Agents", Hardbook of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Coloring Agents", in Drug Design: harmaceutical Coloring Agents harmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Coloring Agents harmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Coloring & Drug Design: harmaceutical Coloring & Drug Design: harmaceutical Coloring & Drug Design: harmaceutical Association & the Pharmaceutical Society of Great Britain, pp. 81-90 (1965). harmaceutical Coloring & Drug Design: harmaceutical Coloring & Drug De
/	م ا	namaceutical Association & the Friance An Overview, Bioreversible Carriers in 10 (1987)
	FDT	narmaceutical Association & the Fluid Properties of the Properties
1	150 13	akeru Higuchi, "Prodrug & Drug Delivery Systems", ACS Symposium Series 14, heory and Application, Edward B. Roche, Ed., Pergamon Press, New York, pp. 1-12, heory and Application, Edward B. Roche, Ed., Prodrugs as Novel Drug Delivery Systems", ACS Symposium Series 14, Higuchi et al., Eds., "Prodrugs as Novel Drug Delivery Systems", ACS Symposium Series 14, Higuchi et al., Eds., "Prodrugs as Novel Drug Delivery Systems", ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems", ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium Series 14, Higuchi et al., Prodrugs as Novel Drug Delivery Systems (Novel Drug Delivery Systems), ACS Symposium (Novel Drug Delivery Systems), ACS Symposium (N
	╺┪══ ╂╡	Higushi et al. Eds., Pro-drugs as Noval Drug Date (1975)
	165 1	Higuchi et el, Eds., Pro-drugs as Noval Drug (1975). Merican Chemical Society, Wash., D.C., pp. 1-115 (1975). Merican Chemical Society, Wash., D.C., pp. 1-115 (1975).
		Higuchi et al, Eds., "Pro-drugs as Novel Drugs as N
	\FF \ \	Holmquist et al, "Actions of 3-Morpholinosydnoninin (Oct. 1993). Holmquist et al, "Actions of 3-Morpholinosydnoninin (Oct. 1993). Issue", Journal of Urology, Vol. 150, No. 4, pp. 1310-1315 (Oct. 1993). Holmquist et al, "Effects of the nitric oxide synthase inhibitor No-nitro-L-arginine on the erectile. Holmquist et al, "Effects of the nitric oxide synthase inhibitor No-nitro-L-arginine on the erectile. Holmquist et al, "Effects of the nitric oxide synthase inhibitor No-nitro-L-arginine on the erectile. Holmquist et al, "Actions of 3-Morpholinosydnoninin (Oct. 1993).
		"seue", Journal of Urology, Vol. 1321. Holmquist et al, "Effects of the nitric oxide synthase inhibitor N°-nitro-L-argmitte ut the 1-december of the nitric oxide synthase inhibitor N°-nitro-L-argmitte ut the 1-december of the nitric oxide synthase inhibitor N°-nitro-L-argmitte ut the 1-december of the nitric oxide synthase inhibitor N°-nitro-L-argmitte ut the 1-december of the 1-decembe
	FG	Holmquist et al., Due nerve stimulation in the rabbit. Ada Physiol Court.
,	- 1 11	esponse to cave note the second of the secon
		esponse to cavernous herve sufficients. 1991). Sue Ellen Jackson et al. "Erectile Dysfunction: Therapy Health Outcomes", Outcomes Research, Sue Ellen Jackson et al. "Erectile Dysfunction: Therapy Health Outcomes", Outcomes Research, Sue Ellen Jackson et al. "Erectile Dysfunction: Therapy Health Outcomes", Outcomes Research,
	FH	Sue Ellen Jackson et al. C. House St. L. Hou
		DETAIL (DC FISHVIR) (DOWN 14) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	FI	T. Katsushima et al., Structure-Activity Relationships of a Syctomy, 1906-1910. Antagonists of Adenosine Receptors, J. Med. Chem., 1990, 33, pp. 1906-1910. Antagonists of Adenosine Receptors, J. Med. Chem., 1990, 33, pp. 1906-1910.
i	1 1	Antadonists of Antilosina recognition in the contract of the c
	FJ	Yasuo Kawanishi et al, "Double-blind Abotrect no. 1858-1881 (Oct. 1992).
	1,01	Yasuo Kawanishi et al, "Double-Blind Trial of Oral Prostagrament (Oct. 1992). Urological Association. Vol. 83, No. 1, Abstract, pp. 1656-1661 (Oct. 1992). Urological Association et al. "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J.
	FK	Yasuo Kawanishi et al., Uol. 83, No. 1, Abstract, pp. 1656-1661 (Oct. 1992). Urological Association, Vol. 83, No. 1, Abstract, pp. 1656-1661 (Oct. 1992). Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Korennan et al., "Treatment of Vasculogenic Sexual Dysfunction with Pentoxifylline," J. Stanley G. Stanley G
	ן יין	Stanley G. Korenman et al, "Treatment of Vascount 1993). Am. Gerletrics Soc., Vol. 41, No. 4, pp. 363-366 (April, 1993). Robert J. Krane et al, "Impotence", New England Journal of Medicine, Vol. 321, No. 24, pp. 1648-
	 - -	
	FL	1658 (Dec. 14, 1989). Kremzer, et al., "Synth. & Blol. activity of diprophylline anal.", Khim-Farm. Zh., 15/6,59-
		Most of al "Synth, & Blol. activity of diprophylline Bnail., Nilling and Synth, & Blol. activity of diprophylline Bnail.
1	FIM	CAS ABS '81:632818.
		Kremzer, et al., "Synth. a Stat. States of Kremzer, et al., "Synth. a States of Algorithms of Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in W.R. Kukovatz et al, "Evidence for Cyclic GMP-Mediated Relexant Effects of Nitro-Compounds in Nitro-Co
	(FN	
1	i	138 (1979). Y M. Lin et al, "The rabbit as an intracavemous injection study model", Urol. Res. Vol. 24, pp.
ــــــــــــــــــــــــــــــــــــــ		138 (1873). The rephit as an intracavemous injection study model, 576. 765
ГТ	FO.	Y M. Lin et al., The rabbit do at 1996. 27-32 (1996). Tom F. Lue, "Topical and Oral Agents for Erectile Dysfunction", J. Formos Med. Assoc, Vol. 98, Tom F. Lue, "Topical and Oral Agents for Erectile Dysfunction", J. Formos Med. Assoc, Vol. 98, 1999.
1 L		27-32 (1996). "Tracked and Oral Agents for Erectile Dysfunction", J. Formos Meu. Assoc, Vol.
	FP	No. 4, pp. 233-241(March 9, 1999). James A. Lugg et al, "The Role of Nitric Oxide in Erectile Function," J. of Andrology, Vol. 16, No.
1 1		No. 4, pp. 233-24 (March Pole of Nitric Oxide in Erectile Function," J. of Anarology, Vol. 10, 110
	FQ	James A. Lugg et al., The Role of Mills
1 1	1 _	14 == 2 / (lan /Peu, 1993);
-	FR	E.G. McMahon et al., Ophresson and Phoenhodiesterase Inhibitor, Journal of Pharmacology and
1 1		
1 .1	1	3',5'-Monophosphate-Selective Prospination (1989). Experimental Therapsutics, Vol. 2513, pp. 1000-1006 (1989). Experimental Therapsutics, Vol. 2513, pp. 1000-1006 (1989).
 - 	TFS	
1 1	Ι, Ψ	Impotence Research, vol. 5, pp. 11 all colors of SIN-I in Rabbit and Man: Functional and
 	— FI	
1 1	ן רי	M.F. Meyer et al, "Intracavemous Application of Circle 179-182 (1993). Toxicological Results", Ann. Urol., Vol. 27, No. 3, pp. 179-182 (1993). Toxicological Results", Ann. Urol., Vol. 27, No. 3, pp. 179-182 (1993).
1 1	FL	Alvaro Morales et al. "Oral and Topical Programme Alvaro Morales et al. "Oral and Topical Progra
		Morley "Management of Impotence, Diagnostic Considerations and
	F	
<u> </u>		Impotence, Vol. 93, No. 3, pp. 85-87, 71-72 (Feb. 15, 1993). Impotence, Vol. 93, No. 3, pp. 85-87, 71-72 (Feb. 15, 1993). Murray, K.J., Phosphodiesterase V _A Inhibitors, DN&P 6(3), pp. 150-155, April 1993.
	FV	/ Impotence, Vol. 35, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3), pp. 150-153, April 1995. / Murray, K.J., Phosphodiesterase V. Inhibitors, DN&P 6(3
	F)	(C. David Nicholson et al., "Interestide phosphodiesterase isoenzymes", Frends in
1		I - L Maria Tabliance of Cyclic Huddonov Privicina
	1 1	Pharmacological Sciences, Vol. 12. Pp
 	TF.	A Namingki P., et al., Syllette 1 Tourist A (4074) (in Dolleh)
1		Dwinterloksantyny, ACIA (CONT. 1987)
\	 	
ŀ		dispeth transfer Acta, Folding Filanting 1 - dispetation 5 Inhibitor Potentiales uto
 	 	A Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 3 inhibitor. A Ohnishi M., et al., (1999) E4021, a Selective Phosphodiesterase 3 inhibitor. Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide in Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs. Journal of Vasodilator Effect of Inhaled Nitric Oxide In Isolated Perfused Rat Lungs.
1	ا ا	
	1	Vasodilator Effect of Intelest No. 10 Vasodilator Effect No. 10 Vasodilator Effet No. 10 Vasodilat
<u> </u>	 	The test of the second transfer of the second secon
Γ	1 6	B Elizabeth Paimer, Waking States
. L	<u></u>	1999) C Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21. C Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21. Region Francisco Company, 56" Ed., pp. 2534-37 (2001)
-		C Pfizer, "Erectile Dysfunction", 1998 Annual Report, p. 21. Physicians' Desk Reference, Medical Economics Company, 55 th Ed., pp. 2534-37 (2001) Physicians' Desk Reference, Medical Economics Company, 46th Ed., pp. 1099-1100 (1992).
	V/(0	D Physicians' Desk Reference, Medical Economics Company, 35 Ed., pp. 1099-1100 (1992). Physician's Desk Reference, Medical Economics Company, 46th Ed., pp. 1099-1100 (1992). Physician's Desk Reference, Medical Economics Company, 46th Ed., Product Identification
	7	F Physician's Desk Reference, Western Company Afth Ed., Product Identification
	V41/	F Physician's Desk Reference, Medical Economics Company. Dayton Himbin Tablets and Yohimex Tablets, pp. 409, 905 & 1190 (1992)
}	5 //	Dayton Himbin Tablets and Tollings
<u> </u>		had him to
AA EBAUA A	T AMOMAA	100.50 PM Fantam Budiate Time 12 COM/ICOTA EEVDE 414 1 PMID:0700000 2 ANIB:000 DAD 6405 2 PM PATION TIME ANIAG 44

Page 5 of 6

	AVE	GT.	Jacob	Rajfer et al, "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavemosum in onse to Nonadrenergic, Noncholinergic Neurotransmission", New England Journal of No. 2, pp. 90-94 (Jan. 9, 1992)
\mathcal{M}	5	- 11	Respo	onse to No. 10. 2 no. 90-94 (Jan. 9, 1992)
P		•	Medic	1/16. VUI. 0201 102 102 102 102 102 102 102 102 10
	ľ	•	$\Delta \Delta \Delta = X$	BICASE IN ACCUMULATION OF THE PROPERTY OF THE
		GI	Remi	ngton's Pharmaceutical Sciences, Colding, 1990) laro, Ed., Mack Publishing Co., pp. 1288-1300 (1990) laro, Ed., Mack Publishing Co., pp. 1288-1300 (1990) lington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1990 (1990) lington's Pharmaceutical Sciences, 18th Ed., A.R. Gennaro, Ed., Mack Publishing Co., pp. 1990 (1990)
_1		- 1	Genn	aro, Ed., Mack. 19 Janear 19th Ed. A.R. Gerillaro, Ed., Macket 19 Janear 19th Ed. A.R. Gerillaro, Ed., Macket 19th Ed., Ed., Mack
	_	GJ	1519	-1712 (1990) — Grantilo Distrinction", International Journal of STD & AIDS, Vol.
		GK	Alan	Ington's Pharmaceutical Sciences, Touristic Ington In
l		. '	17, SL	ippi s, pp. 19 otheris and biological activity of 3-116-117 (1996)
		GL		
		GM	Ray	Romanenko et al. "Synthesis and cyclohexylaminoxenthines", Chemical Abstracts, 106: 905771 (1997) rocyclic, and cyclohexylaminoxenthines", Chemical Abstracts, 106: 905771 (1997) rocyclic, and cyclohexylaminoxenthines", Chemical Abstracts, 106: 905771 (1998) rocyclic, and cyclohexylaminoxenthines of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of erectile mond C. Rosen et al., "The process of care model for evaluation and treatment of evaluation and tr
1		L	dysf	mond C. Rosen et al., "No. 1 Impotence Research, Vol. 11, pp. 35-14 Selective PDE5 unction", International Journal of Impotence Research, Vol. 11, pp. 35-14 Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: Potent and Selective PDE5 id P. Rotella et al., "N-3-Substituted Imidazoquinazolinones: PDE5 id P. Rotella et al., "N-3-Substituted Imidazoq
		GN	Dav	function", International Journal of Inidazoquinazolinones: Potent and Selective Vol. 43, No. bitors as Potential Agents for Treatment of Erectile Dysfunction", J. Med. Chem, Vol. 43, No. bitors as Potential Agents for Treatment of Erectile Dysfunction", J. Med. Chem, Vol. 43, No. bitors as 2000 (2000)
,	}	1	17 n	n 125/-1203 (2000) ladunod Aethma by an Orally Austria
	+-	GO	Rot	bitors as Potential Agents to provide the provided Assistance of Potential Agents of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al, "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by an Orally Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise-Induced Assistance by Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise by Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise by Absorbed Assistance by Absorbed Mast Cell pin M. Rudd et al., "Inhibition of Exercise by Absorb
		١ _	Sta	bilizer (M & B Zingary Tylerability and Pharmacokinetics of the 2000)
	1	GP	I From	CINE DYSIGNOCIONI LA STREET CONTROL PROSPROGRESSO (302)
	┼	GC	1 T.	Saeki & I. Salto, "Isolation of Cyclic Nucleotide 1 Nucle
	1		Bio	chemical Pharmacourage Sunthesis of Tricyclic Purine Delivatives
		GF	3 Jui	nichi Shimada et al. "A Convenieri Symmetric Shimada et al. "A Convenieri Symmetric Shimada et al. "A Convenieri Symmetric Shimada et al. "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrata instian G. Stief et al. "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrata instian G. Stief et al. "Preliminary Results with the Nitric Oxide Donor Linsidomine Chlorhydrata institution", The Journal of Urology, Vol. 148, No. 5, pp.
	+-	- G	5 Ch	nemistry, Vol. 30, pp. 24. "Preliminary Results with the Nitric Oxide Donor Litisadmin of United Human Erectile Dysfunction", The Journal of Urology, Vol. 148, No. 5, pp. the Treatment of Human Erectile Dysfunction", The Journal of Urology, Vol. 148, No. 5, pp. the Treatment of Human (No. 1992)
			in	the Treatment of Human Erecule Dysians.
		ᆛᇎ	- 114	the Treatment of Human Erectic Systems of the Present of the nitric oxide donor SIN-1 on human 37-1440 (Nov. 1992) Inistian G. Stief et al., "Preliminary report on the effect of the nitric oxide donor SIN-1 on human tipsels in vivo", World J. Urol, Vol. 9, pp. 237-239 (1991)
1		اد	Ca	nristian G. Stief et al, "Preliminary report of the Short 239 (1991) wemous tissue in vivo", World J. Urol, Vol. 9, pp. 237-239 (1991) wemous tissue in vivo", World J. Urol, Vol. 9, pp. 237-239 (1991) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian G. Stief et al, "The Effect of the Specific Phosphodiesterase (PDE) inhibitors on Human hristian Human hristian Human hristian Human hristian hristian hristian hristia
-	+	G	UCI	nristlan G. Stier et al. The Little and in Vivo," J. of Urology. Am. Urological Assessing
1	1	- }	ar	nd Rabbit Cave (4008)
<u> </u>		-\-	V P	nd Rabbit Cavernous Tissue in Visual III Visual II Visual III Visu
1	1	٦	8	Taher et al., "Priosphotics", The Journal of Urology, Vol. 149, No. 4, p. 285 (Adstract)
-	_		A W	. Taher et al. "Control of Verlous Selective Inhibitors", Int. J. Imporence Ass., "Verlous Selective Inhibitors", Int. J. Imporence Inhibitors
1	1	Ì	100	11 (1992)
-	╅		3X Y	Auscle and the Eriect of Values of Substituted 8-Aminopurine Derivatives, Bulletine of the .11 (1992) Yoneda, F. et al., A New Synthesis of Substituted 8-Aminopurine Derivatives, Bulletine of the Chemical Society of Japan, Vol. 46, pp. 1836-1839 (1973). Chemical Society of Japan, Vol. 46, pp. 1836-1839 (1973).
1	_		10	hemical Social of all "Pharmacological Effects of Adenositie of Columb
		-	GY j	Toshlastu Takahashi et al., Francisco (1991) Tohoku J. Exp. Med., Vol. 165, pp. 49-58 (1991) Tohoku J. Exp. Med., Vol. 165, pp. 49-58 (1991) Youssef, S. et al., Purines XIV. [1] Reactivity of 8-Bromo-3-9-dimethylxanthine Towards Some Youssef, S. et al., Purines XIV. [1] Reactivity of 8-Bromo-3-9-dimethylxanthine Towards Some Youssef, S. et al., Purines XIV. [1] Reactivity of 8-Bromo-3-9-dimethylxanthine Towards Some
-	-+-		GZ	Youssel, S. et al., Purines XIV. [1] Reactivity of 6-Biothio
1	- 1		11	Nucleophilic Reagestos, and Relatation and Relatation in the
			HA	Harvey C. Taub et al, "Relationship between Contraction (Dec. 1993) Corpus Cavernosum", Urology, Vol. 42, No. 6, pp. 698-704 (Dec. 1993) Corpus Cavernosum", Urology, Vol. 42, No. 6, pp. 698-704 (Dec. 1993)
L	\dashv		UR I	Harvey C. Taub et al, "Relationship between the property of th
	[W. Joseph Thompson, "Cyclic Notice 1806 1991) Function", Pharmac, Ther., Vol. 51, pp. 13-33 (1991) Function", Pharmac, Ther., Vol. 51, pp. 13-33 (1991) Flavio Trigo-Rocha et al, "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Flavio Trigo-Rocha et al, "The Role of Cyclic Adenosine Monophosphate, Deurotransmission in Canine Flavio Trigo-Rocha Endothelium and Nonadrenergic, Noncholdinergic Neurotransmission in Canine
卜	$\neg \uparrow$		HC I	Flavio Trigo-Rocha et al. The Long depending of Noncholinergic Neuronalistics
}	- 1		1 1	Monophosphate, Endothelium and Nonadrenergic, Noncholitergis (April 1993) Monophosphate, Endothelium and Nonadrenergic, Noncholitergis (April 1993) Penile Erection", Journal of Urology, Vol. 149, No. 4, pp. 872-877 (April 1993) Penile Erection", Journal of Wilde oxide and cGMP: mediators of pelvic nerve-stimulated erection is
F	+		HD	Monophosphate, Endothelium and Novice No. 4, pp. 872-877 (April 1993) Penile Erection", Journal of Urology, Vol. 149, No. 4, pp. 872-877 (April 1993) Penile Erection", Journal of Urology, Vol. 149, No. 4, pp. 872-877 (April 1993) Penile Erection", Journal of Urology, Vol. 149, No. 4, pp. 872-877 (April 1993) Flavio Trigo-Rocha et al, "Nitro oxide and cGMP: mediators of pelvic nerve-stimulated erection in Monkeys," Neurology and dogs", Am. J. Physiol., Vol. 264, pp. H419-H422 (1993)
			1 1	dogs", Am. J. Physical Mechanism of Penile Erection in Victoria
T			HE	Flavio Trigo-Rocho et al., "Intraceitala Virodynamics, Vol. 13, pp. 71-80 (1994) Urodynamics, Vol. 13, pp. 71-80 (1994) Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers Flavio Trigo-Rocho et al., "The Effect of Intracevernous Injection of Potassium Channel Openers
-	}		HF	Urodynamics, Vol. 13, pp. 71-50 (1954) Flavio Trigo-Rocho et al. The Effect of Intracavernous Injection of Potassium Chainter Open Flavio Trigo-Rocho et al. The Effect of Intracavernous Injection of Potassium Chainter Open Flavio Trigo-Rocho et al. The Effect of Intracavernous Injection of Potassium Chainter Open Flavio Trigo-Rocho et al. The Effect of Intracavernous Injection of Potassium Chainter Open Flavior Intracavernous Injection of Potassium Chainter Intracavernous Injection Intracavernous Inje
1	}		"	in Monkeys and Dogs, was or say
1			1	(1995) And Scalium Nitroonisside; Physiologic Effects as a Vol. 7, pp. 49-56 (1995)
ſ		7	HG	Flavio Trigo-Rocho et al. Soldin Nichael C. Trigo-Rocho et al. Soldin Nichael C. Trigo-Rocho et al. Soldin Nichael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Michael C. Trigo et al. "Role of the Nitric Oxide Donor Linsidomine Chlorhydrate (SIN-1) in the Nitric Oxide Donor Linsidomine Chl
	<u> </u>	(-7	PHH	Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Michael C. Truss et al, "Role of the Nitric Oxide Donor Linsidomine Chiamydrate (Cit.) Diagnosis and Treatment of Erectile Dysfunction," Urology. Vol. 44, No. 4, pp. 553-556 (Oct.)
1		مؤسم		Diagnosis and Treatment of Live
,	1 1	/	1_	1994) 59 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-114 * DNIS:8729306 * CSID:908 298 5405 * DURATION (mm-ss):05-44

Page 6 of 6

_	Sp		Subbarao Vernulapalli et al. "Antiplatelet and Antiproliferative Effects of SCH 51866, a Novel Type 1 and Type 5 Phosphodiesterase Inhibitor", Journal of Cardiovascular Pharmacology, Vol. 28, pp. 862-869 (1998) Richard J. Weiss, "Effects of Antihypertensive Agents on Sexual Function," Am. Family Physician, Richard J. Weiss, "Effects of Antihypertensive Agents on Sexual Function," Am. Family Physician, Richard J. Weiss, 2075 2082 (Dac. 1991)
١.	1 1		Richard J. Weiss, Effect (Dec. 1981) Vol. 44, No. 6, pp. 2075-2082 (Dec. 1981) Vol. 44, No. 6, pp. 2075-2082 (Dec. 1981)
r		HK	Vol. 44, No. 6, pp. 2075-2082 (Dac. 1991) Vol. 44, No. 6, pp. 2075-2082 (Dac. 1991) E. Douglas Whitehead et al. Treatment alternatives for impotence", PGM Symposium, Vol. 88, No. 2 pp. 139-149, 152 (August 1990) Chackalamannii, Application # 09/940,760, Filed 08/28/2001
Н		HL	
\vdash	_ + _		Asberom, Application #10/22/11/0.
\vdash		HN	Acharam Application #10/290,011.7 800 11.000 11.000 11.000 02/45/2002
┝		HO	Asberom, Application #10/290,011. Filed 11/07/2002 PCT International Search Report for PCT US 01/28983 mailed 02/15/2002 PCT International Search Report for PCT US 01/28983 mailed 02/15/2002 PCT International Search Report for PCT US 01/28983 mailed 02/15/2002
t	an	HP	XP-002188426. Synthesis and biological Abstracts, Columbus, Chib, GS, No. heterocyclic, and cyclohexylaminoxanthines, 6001 Chemical Abstracts, Columbus, Chib, GS, No.
1	0	<u> </u>	106:95677n, (1987).
٦		<u> </u>	
٦		Ι	
t		Γ	
ı		1	
t		Τ.	
·			
ŀ		7	
	EXAMINE	R	DATE CONSIDERED 1865 Well of the Considered of
		'	Well AGED 609. Draw line
		<u>. </u>	initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line in conformance and not considered. Include copy of this form with next communication to
	*EXAMIN	ER:	on initial if reference considered, whether or not citation is in conformance with MFD communication to initial if reference considered, whether or not conformance and not considered. Include copy of this form with next communication to in it not in conformance and not considered.
	through c	HEATHO	n if not in conformation and the
	annticant		

46737_1.DOC